PDS Biotechnology amends promissory note with YA II PN

On August 31, 2026, PDS Biotechnology Corporation entered into a First Amendment to Promissory Note with YA II PN, Ltd., amending a promissory note originally issued on June 15, 2026 in the amount of $6,000,000.¹

The amendment makes three main changes. It requires the company to deliver weekly remittance notices to the holder disclosing net proceeds from sales under its at-the-market offering program during the prior week, with payment of the applicable portion due within one business day of the notice. It also extends the cure period for a Nasdaq listing deficiency from 75 days to 180 days. Additionally, a new provision requires that 100% of net cash proceeds from any equity or equity-linked financing outside the ATM program be applied as a mandatory deemed redemption payable to the holder within five business days of receipt.¹

The amendment does not take effect immediately. It becomes effective upon execution and delivery by both parties and the company having paid in full the installment amount due on September 14, 2026, under the terms of the note.¹

The company noted that the description in the filing is not complete and is qualified by reference to the full text of the amendment, filed as Exhibit 10.1.¹ The obligations described are also reported under Item 2.03 as the creation of a direct financial obligation of the registrant.¹

The filing was signed on September 4, 2026 by Frank Bedu-Addo, Ph.D., President and Chief Executive Officer of PDS Biotechnology Corporation.¹